#Moffitt Cancer Center

Tampa, FLwfla.com

No monkeypox cases reported in Sunshine State, FDOH says

TAMPA, Fla. (WFLA) — Monkeypox is reportedly back in the United States. The United States Centers for Disease Control and Prevention says there’s only one case in the country, but is monitoring hundreds of people who were possibly exposed. The Chief of Infectious Diseases at Moffitt Cancer Center Dr. Jon...
Picture for No monkeypox cases reported in Sunshine State, FDOH says
Beauty & Fashionneighborhoodnewsonline.net

Pasco Dental Adds Former Wharton State Champ To Fold

In almost every medical-related field these days, one visit to the doctor could mean multiple trips to see multiple specialists. Sore throat? Bad back? Throbbing knee?. Specialist, specialist, specialist. And, dentistry usually is no different, which is why Daniel Hwang, D.D.S., of Pasco Dental takes great pride in his advanced...
Picture for Pasco Dental Adds Former Wharton State Champ To Fold
Florida Statewatermarkonline.com

Florida businesses call on Congress to pass Equality Act

(Washington Blade file photo by Michael Key) ORLANDO | More than 20 major businesses across Florida came together July 21 to support passage of the Equality Act, releasing an open letter to Congress. The federal legislation would improve civil rights and modernize laws by adding permanent protections for members of...
Boston, MAonclive.com

The Evolving Treatment Landscape of HNSCC

A brief overview of treatment advances for HRAS-mutated head and neck squamous cell carcinoma. Glenn J. Hanna, MD: Hello, my name is Glenn Hanna. I’m a medical oncologist in the Center for Head and Neck Oncology at Dana-Farber Cancer Institute in Boston, Massachusetts. I’m joined today by Dr Nabil Saba. He is the head and neck cancer program director at Emory University in Atlanta, Georgia. We’re thrilled to talk to you a bit today about the HRAS-mutated head and neck cancer landscape.

Lutathera supports improved survival for patients with neuroendocrine tumors

Lutathera from Novartis is indicated to treat somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors, which include foregut, midgut and handout neuroendocrine tumors in adults. The drug was the focus of a recent presentation World Congress on Gastrointestinal Cancer 2021 where Dr. Jonathan R. Strosberg, presented positive survival data concerning the drug. Strosberg...

Dr. Costa Discusses Ongoing Research Efforts in TNBC

Ricardo Costa, MD, MSc, discusses ongoing research efforts in triple-negative breast cancer. Ricardo Costa, MD, MSc, medical oncologist, Department of Breast Oncology, Clinical Investigator Track, Moffitt Cancer Center, discusses ongoing research efforts in triple-negative breast cancer (TNBC). Although drug development has not moved as rapidly in TNBC as it has...

Choosing a BTK Inhibitor for MCL: Consider Side Effects and Insurance Coverage

When patients with mantle cell lymphoma are discussing the use of a BTK inhibitor, they must consider what their insurance will cover, as well as current health complications and potential side effects. When choosing a Bruton tyrosine kinase (BTK) inhibitor for the treatment of mantle cell lymphoma (MCL), the decision...
Pasco County, FLpascoedc.com

Moffitt Cancer Center Joins Pasco EDC Board Ahead of New Expansion

PASCO COUNTY, FLORIDA (July 19, 2021) — The Pasco Economic Development Council (Pasco EDC) is excited to announce a new Policy Council and Board of Directors member joining from H. Lee Moffitt Cancer Center & Research Institute, Inc. (Moffitt). Moffitt has recently announced their plans for an expansion campus in...

Cross-Resistance: One Cancer Therapy Can Undermine the Next

Targeted therapy and immunotherapy are often employed as a one-two punch to treat certain cancers, but sometimes this approach falls short. In a study published on July 15 in Nature Cancer, researchers found that dendritic cells, cells crucial for activating the immune system during immunotherapy, were less active and less numerous in mouse models of melanoma that had become resistant to targeted therapy, explaining why these tumors were less sensitive to immunotherapy. Stimulating dendritic cells restored the tumors’ response to immunotherapy.